Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent

Pharmacological Research

Volumn 56, Issue 1, 2007, Pages 42-48

  Comini, L ^a   Bachetti, T ^a   Cargnoni, A ^a   Bastianon, D ^a   Gitti, G L ^a   Ceconi, C ^b   Ferrari, R ^b  

^a IRCCS   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

ACE inhibitor; Bradykinin; Cardiac myocyte; Endothelium; NO synthase

Indexed keywords

CITRULLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRATE; NITRIC OXIDE; NITRITE; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; HEART MUSCLE CELL; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA; BLOOD PRESSURE; ENALAPRIL; IMMUNOBLOTTING; INDOLES; MALE; MYOCYTES, CARDIAC; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; PERINDOPRIL; RAMIPRIL; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROISOQUINOLINES;

EID: 34250848482     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.03.004     Document Type: Article

References (50)

1. Riordan J.F. Angiotensin-I-converting enzyme and its relatives. Genome Biol 4 (2003) 225-231
2. Zisman L.S. Inhibiting tissue angiotensin-converting enzyme. A pound of flesh without the blood?. Circulation 98 (1998) 2788-2790
3. Linz W., Wiemer G., Gohlke P., Unger T., and Scholkens B.A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47 (1995) 25-49
4. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. [Erratum in JAMA. 1995;274:462]. JAMA 273 (1995) 1450-1456
5. Acharya K.R., Sturrock E.D., Riordan J., and Ehlers M.R.W. ACE revisited: a new target for structure-based drug design. Nat Rev Drug Discov 2 (2003) 891-902
6. Cushman D.W., Wang F.L., Fung W.C., Harvey C.M., and DeForrest J.M. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 8 (1989) 294-306
7. Johnston C.I. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension 23 (1994) 258-268
8. Bhoola K.D., Figueroa C.D., and Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44 (1992) 1-80
9. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
10. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., and Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
11. Braunwald E., Domanski M.J., Fowler S.E., Geller N.L., Gersh B.J., Hsia J., et al., PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
12. Pitt B., O'Neill B., Feldman R., Ferrari R., Schwartz L., Mudra H., et al., QUIET Study Group. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 87 (2001) 1058-1063
13. Moncada S., Palmer R.M.J., and Higgs E.A. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43 (1991) 109-142
14. Moncada S., and Higgs A. The l-arginine-nitric oxide pathway. N Engl J Med 329 (1993) 2002-2012
15. Varin R., Mulder P., Tamion F., Richard V., Henry J.P., Lallemand F., et al. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation 102 (2000) 351-356
16. 2 receptors and angiotensin-I converting enzyme in CHO cells. Circ Res 81 (1997) 848-856
17. Pelat M., Massion P.B., and Balligand J.L. Nitric oxide "at heart": emerging paradigms after a decade. Arch Mal Coeur Vaiss 98 (2005) 242-248
18. Comini L., Bachetti T., Gaia G., Pasini E., Agnoletti L., Pepi P., et al. Aorta and skeletal muscle NO-synthase expression in experimental heart failure. J Mol Cell Cardiol 28 (1996) 2241-2248
19. Comini L., Boraso A., Bachetti T., Bernocchi P., Pasini E., Bastianon D., et al. Effects of endotoxic shock on neuronal NOS and calcium transients in rat cardiac myocytes. Pharmacol Res 51 (2005) 409-417
20. Lowry O.H., Rosenbourgh N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
21. Laemmli U.K. Cleavage of structural proteins during assembling of the head of bacteriophage T4. Nature 277 (1970) 680-685
22. Schulz R., Panas D., Catena R., Olley P., Moncada S., and Lopaschuk G. The role of nitric oxide in cardiac depression induced by interleukin-1β and tumour necrosis factor-α. Br J Pharmacol 114 (1995) 27-34
23. Granger D.L., Taintor R.R., Boockvar K.S., and Hibbs Jr. J.B. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol 268 (1996) 142-151
24. Moshage H., Kok B., Huizenga R.H., and Jansen P.L.M. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 41 (1995) 892-896
25. Waeber B., Nussberger J., Jillerat L., and Brunner H.R. Angiotensin converting enzyme inhibition: discrepancy between anti-hypertensive effect and suppression of enzyme activity. J Cardiovasc Pharmacol 14 Suppl. 4 (1989) S53-S59
26. Hoshida S., Kato J., Nishino M., Egami Y., Takeda T., Kawabata M., et al. Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation 103 (2001) 630-633
27. Soubrier F., Alhenc-Gelas F., Hubert C., Allegrini J., John M., Tregear G., et al. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA 85 (1988) 9386-9390
28. Wei L., Alhenc-Gelas F., Corvol P., and Clauser E. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem 266 (1991) 9002-9008
29. Georgiadis D., Beau F., Czarny B., Cotton J., Yiotakis A., and Dive V. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin. Circ Res 93 (2003) 148-154
30. Li H., Wallerath T., and Fostermann U. Physiological mechanisms regulating the expression of endothelial-type NO synthase. Nitric Oxide 7 (2002) 132-147
31. Wiemer G., Linz W., Hatrik S., Scholkens B.A., and Malinski T. Angiotensin converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. Hypertension 30 (1997) 1183-1190
32. Bachetti T., Comini L., Pasini E., Cargnoni A., Curello S., and Ferrari R. ACE-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats. J Mol Cell Cardiol 33 (2001) 395-403
33. Cargnoni A., Comini L., Bernocchi P., Bachetti T., Ceconi C., Curello S., et al. Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril. Br J Pharmacol 133 (2001) 145-153
34. Loscalzo J., and Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 38 (1995) 87-104
35. 1 receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 39 2 Part 2 (2002) 634-638
36. 2 receptor pathway. Circ Res 89 (2001) 678-683
37. Veeravalli K.K., and Akula A. Involvement of nitric oxide and prostaglandin pathways in the cardioprotective actions of bradykinin in rats with experimental myocardial infarction. Pharmacol Res 49 (2004) 23-29
38. Schafer A., Fraccarollo D., Tas P., Schmidt I., Ertl G., and Bauersachs J. Endothelial dysfunction in congestive heart failure: ACE inhibition vs angiotensin II antagonism. Eur J Heart Fail 6 (2004) 151-159
39. Remme WJ. Prevention of cardiovascular events by perindopril in patients with stable coronary artery disease does not depend on blood pressure and its reduction-Results from the EUROPA study. Circulation. 2004; 110:III628. [Abstract 2919].
40. Poole-Wilson P.A., Lubsen J., Kirwan B.A., van Dalen F.J., Wagener G., Danchin N., et al. A coronary disease trial investigating outcome with nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 364 (2004) 849-857
41. Ceconi C., Fox K.M., Remme W.J., Simoons M.L., Bertrand M., Kluft C., et al. Effect of perindopril in patients with stable coronary artery disease: results of the pertinent sub-study. J Hypertens 23 (2005) S274
42. Johnston C.I., Fabris B., Yamada H., Mendelsohn F.A., Cubela R., Sivell D., et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 7 (1989) S11-S16
43. Massion P.B., Feron O., Dessy C., and Ballligand J.L. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 93 5 (2003) 388-398
44. Massion P.B., Pelat M., Belge C., and Balligand J.L. Regulation of the mammalian heart function by nitric oxide. Comp Biochem Physiol A Mol Integr Physiol 142 2 (2005) 144-150
45. du Toit E.F., Genade S., Carlini S., Moolman J.A., Brunner F., and Lochner A. Efficacy of ischaemic preconditioning in the eNOS overexpressed working mouse heart model. Eur J Pharmacol 556 1-3 (2007) 115-120
46. Bryan N.S., Fernandez B.O., Bauer S.M., Garcia-Saura M.F., Milsom A.B., Rassaf T., et al. Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. Nat Chem Biol 1 5 (2005) 290-297
47. Bryan N.S., Rassaf T., Maloney R.E., Rodriguez C.M., Saijo F., Rodriguez J.R., et al. Cellular targets and mechanisms of nitros(yl)ation: an insight into their nature and kinetics in vivo. Proc Natl Acad Sci USA 101 12 (2004) 4308-4313
48. Sigurdsson A., Amtorp O., Gundersen T., Nilsson B., Remes J., Swedberg K., and The Ramipril Trial Study Group. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. Br Heart J 72 5 (1994) 422-427
49. Erikson S.V., Eneroth P., Kjekshus J., Offstad J., and Swedberg K. Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: a subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Clin Cardiol 17 11 (1994) 603-606
50. Sharifi A., Akbarloo N., and Darabi R. Investigation of local ACE activity and structural alterations during development of L-NAME-induce hypertension. Pharmacol Res 52 (2005) 438-444